Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
layoffs
Biotech
Alector halves staff after GSK-partnered antibody fails in ph. 3
To pivot away from latozinemab, the Bay Area biotech is laying off 49% of its staff, while the company’s R&D head is resigning effective Dec. 22.
Darren Incorvaia
Oct 22, 2025 11:23am
Fierce Biotech Layoff Tracker 2025: Alector, Galapagos & more
Oct 22, 2025 11:00am
Galapagos to wind down cell therapy unit, threatening 365 jobs
Oct 21, 2025 9:30am
Kezar plans layoffs after FDA axes meeting to discuss next trial
Oct 17, 2025 8:55am
Novo ends all cell therapy R&D, lets go of staff
Oct 10, 2025 3:30pm
Big pharma cuts and gene therapy woes: Inside Q3's layoffs
Oct 3, 2025 4:30pm
